Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Hearing Loss 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

Specimen Handling 200Magnetic Resonance Spectroscopy 160pembrolizumab 153Carboplatin 117Biopsy 108Cyclophosphamide 100Cisplatin 91Paclitaxel 78Gemcitabine 67Bevacizumab 66Nivolumab 59fludarabine 57Radiotherapy 54Fluorouracil 52Dexamethasone 47Capecitabine 46Oxaliplatin 45Doxorubicin 44Docetaxel 44Pemetrexed 43Rituximab 42Leucovorin 42venetoclax 40durvalumab 38atezolizumab 36Radiation 36Standard of Care 34Prednisone 33Injections 32Cetuximab 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Atorvastatin × 30 days × Clear all
NCT04915183 2026-05-22

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
224 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hearing Loss

NCT03819101 2026-05-06

PEACE-4

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Recruiting
1,210 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡